bioRxiv · 10.1101/2020.09.16.299891
High affinity modified ACE2 receptors prevent SARS-CoV-2 infection
Abstract
The SARS-CoV-2 spike protein binds to the human angiotensin-converting enzyme 2 (ACE2) receptor via receptor binding domain (RBD) to enter into the cell and inhibiting this interaction is a main approach to inhibit SARS-CoV-2 infection. We engineered ACE2 to enhance the affinity with directed evolution in 293T cells. Three cycles of random mutation and cell sorting achieved 100-fold higher affinity to RBD than wild-type ACE2. The extracellular domain of modified ACE2 fused to the human IgG1-Fc region had stable structure and neutralized SARS-CoV-2 without the emergence of mutational escape. Therapeutic administration protected hamsters from SARS-CoV-2 infection, decreasing lung virus titers and pathology. Engineering ACE2 decoy receptors with human cell-based directed evolution is a promising approach to develop a SARS-CoV-2 neutralizing drug that has affinity comparable to monoclonal antibodies yet displaying resistance to escape mutations of virus. One Sentence SummaryEngineered ACE2 decoy receptor has a therapeutic potential against COVID-19 without viral escape mutation.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Higuchi, Y., Suzuki, T., Arimori, T., Ikemura, N., Kirita, Y., Ohgitani, E., Mazda, O., Motooka, D., Nakamura, S., Matsuura, Y., Matoba, S., Okamoto, T., Takagi, J., Hoshino, A.. 2020-09-16. High affinity modified ACE2 receptors prevent SARS-CoV-2 infection. https://doi.org/10.1101/2020.09.16.299891
Cite the original work for its findings. Save a collection to share your selection of sources.